Kisqali

KISQALI is a targeted therapy designed to manage certain types of advanced or metastatic breast cancer in adults. It works by selectively inhibiting cyclin dependent kinases 4 and 6 (CDK4/6), which are proteins responsible for cancer cell growth and division. By slowing down the activity of these proteins, KISQALI helps to control tumor progression and supports other systemic therapies in managing disease progression.
Typically, KISQALI is used in combination with hormonal treatments such as aromatase inhibitors or selective estrogen receptor modulators to enhance therapeutic outcomes. The combination approach has shown significant effectiveness in delaying cancer growth and improving progression free survival for patients with hormone receptor positive, HER2 negative breast cancer. The treatment is administered orally in a structured dosing schedule, allowing for convenient at home use under medical guidance.
Common side effects may include neutropenia, nausea, fatigue, and liver function changes, which require regular monitoring through blood tests and clinical check ups. Dose adjustments or temporary interruptions are sometimes necessary to manage these effects safely. Patients are advised to follow a consistent dosing routine and maintain regular consultations with healthcare professionals to ensure optimal results.
KISQALI represents a major advancement in breast cancer management by offering a precise and targeted approach that focuses on the underlying mechanisms of tumor growth. Its integration into combination therapies has improved treatment outcomes and quality of life for many patients navigating advanced stages of breast cancer. Ongoing research continues to explore its broader applications and long term benefits.